الفهرس 
Clinical significance of connexin 32 and connexin 43 expression in acute myeloid leukemia
CONTENTSOnly 14 pages are availabe for public view
 |  | from | 204 |  |  |
| | | from | 204 | | |
Abstract
Cx32 and Cx43 are Gap junctions consist of arrays of intercellular channels. Cx43 is the major component of hematopoietic tissue, Cx32 was also found to be important in bone marrow stromal cells so they may play a role in leukemogenesis. The aim of this study was to evaluate the expression of Connexin 32 and Connexin 43 expression profiles and to correlate their expression with disease severity and other prognostic markers in Egyptian patients with Acute myeloid leukemia. Real time PCR was used to assess the gene expressions patterns in 60 de novo AML patients in addition to 40 normal controls.The study revealed an increased expression of Connexin 32 along with a statistically significant difference between AML de novo patients in comparison to the control group (median Cx32=18,p=0.009). Also Connexin 43 expression showed lower median fold change along with a statistically significant difference between AML de novo patients in comparison to the control group (median Cx43=0.6,p=0.013). The expression of Connexin 32 and Connexin 43 was lower in AML FAB subtype M3 patients with a significant difference against FAB subtypes (M1,M2) and FAB subtypes with monocytic differetiantion (M4,M5) (median Cx32= 0.48, median Cx43= 0.1 and Cx32p=0.009, Cx43p=0.002) with a slight increase of the level of expression in FAB subtypes with monocytic differentiation (M4,M5) against FAB subtypes (M1,M2 and M3) but with no significant difference (median Cx32= 26.5, median Cx43= 0.7 and Cx32p=0.216, Cx43p=0.403). CD 34 positive AML patients showed a significantly higher level of Cx32 and Cx43 expression against CD34 negative AML patients (Cx32p=0.045, Cx43p=0.007). No statistically significant difference was found in Connexin 32 and Connexin 43 fold change expression in AML patients as regards their outcome after first induction. No statistically significant difference was found between favorable risk patients and those with intermediate/unfavourable risk in Connexin 32 and Connexin 43 fold change expression